CCS Research
CCS Facts & Figures
  • Official launch of CCS in 2014

  • Since 2015 CCS constitutes a contractually agreed cancer research network of three partner institutions located in the Salzburg area:

    • Salzburg Cancer Research Institute (SCRI)

    • Paris-Lodron University of Salzburg (PLUS)

    • University Clinics Salzburg (SALK/PMU)

  • CCS joins 14 research groups and two clinical study centers from oncology, oncosurgery, pathology and molecular cancer research

  • CCS Head: Prim. Prof. Dr Richard Greil (SCRI/SALK)

  • CCS Deputy Heads and Co-Founders:

    • Univ.-Prof. Dr. Fritz Aberger (PLUS)

    • Ao. Univ.-Prof. Dr. Alexander Egle (SCRI/SALK/PMU)

  • Scientific Performance and Funding (2010-2017)

    • > 700 publications in peer-reviewed journals

    • > € 16 Mio competitive funding

    • 10 patents

    • since 2003: about 600 clinical trials with 10.000 patients


Translational cancer research at CCS

Bench-to-bedside and bedside-to-bench work

The scientific strategy and conceptual organization of CCS allows both the validation of basic research findings in clinical settings (bench to bedside) and the detailed molecular analysis of clinical observations in predictive in vitro and in vivo model systems (bedside to bench). This bidirectional research strategy accelerates the discovery of novel and innovative therapeutic approaches for personalized cancer therapy. 

Funding & Support

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria


Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria